Studies examining specific AML subtypes have demonstrated deregulated β-catenin and/or merit in targeting the molecule in normal karyotype [47], FLT3 mutant [48], del(5q) [49], myelodysplastic syndrome (MDS) related [50], core binding factor (CBF) mutated [51], and PML-RARα+ [52] AML. The gene discussed is FLT3; the disease is myelodysplastic syndrome.